Bristol Myers Squibb and Nvidia said they will expand their AI computing footprint in a move aimed at building what the companies call the most powerful “AI factory” in life sciences. BMS plans to deploy a NVIDIA DGX SuperPOD enabled with AIDGX Vera Rubin NVL72 systems, extending a collaboration that began when BMS first rolled out DGX infrastructure to support R&D three years ago. The pharma company framed the buildout as a way to increase the probability that programs selected for development are the right ones, tying the compute strategy to pipeline and operational execution. The update also positions BMS alongside other large pharma AI infrastructure efforts, as Nvidia partnerships spread across oncology and diagnostics use cases. For biotech and services providers, the announcement signals continued capital intensity around proprietary compute stacks and the operational shift from isolated pilots toward always-on data-and-model workflows.